CERADON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CERADON is an injectable small-molecule drug approved by Takeda in 1988 with an unknown mechanism of action and indication profile. The product is administered via injection and represents a mature therapeutic asset nearing loss of exclusivity.
LOE Approaching
Moderate competitive pressure (30/100) suggests the brand faces headwinds; expect limited expansion budgets and focus on retention and lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No active job openings are currently linked to CERADON, reflecting its mature lifecycle and approaching loss of exclusivity. Roles on this product would focus on managing decline, maximizing remaining revenue, and preparing for generic competition rather than growth.
Brand ManagerField Sales Representative
Worked on CERADON at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.